Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1. Clear MOA
(1) Nonalcoholic steatohepatitis (NASH) is now the common form of chronic liver disease globally.
(2) Despite its significant health care burden, there are no FDA-approved medications for NASH. Vitamin E and pioglitazone are not applicable to all patients. Obeticholic acid may raise concerns about long-term cardiovascular morbidity.
(3) Inhibition of ACC enzymes pharmacologically provides an attractive approach to treating NAFLD/NASH by decreasing hepatic lipid synthesis while simultaneously increasing fatty acid oxidation.
2. Excellent effect in multiple NASH models.
(1) In HFD induced fatty liver model, asset can significantly reduce serum ALT content, liver TG content and NAS score. The therapeutic effect of each dose group is equivalent to that of GS0976.
(2) In AMLN induced short-term NASH model, All doses of this asset can improve liver function and reduce dyslipidemia, liver lipid accumulation and NAS score. And asset has the same effect as GS0976 (3 mpk) in improving liver fibrosis.
(3) In AMLN induced long-term NASH with liver fibrosis model, asset (5 mpk) can improve liver function and reduce dyslipidemia, liver CHO content, liver lipid accumulation and NAS score.
3. PK&PD: fast oral absorption, high bioavailability, high concentration of liver (target tissue) distribution, and the metabolites in the body are mainly prototype drugs, which are excreted with feces, without obvious drug interaction.
4. Excellent safety for treating NASH.
hERG IC50＞100 μM; no genotoxicity; no cardiovascular, respiratory and central nervous system toxicity
1. Asset type: Acetyl CoA Carboxylase (ACC) inhibitor
2. Indication: NASH
3. Modality: Small molecular
4. Research phase: IND, IP has been granted in the US, CN, etc
5. Cooperation demands: License-out or co-development the global right
6. Research progress:
(1) In AMLN induced long-term NASH with liver fibrosis model, 5 mpk asset can reduce the fibrosis more than 10 mpk GS0976.
(2) The asset has been approved IND.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
This web search service is supported by Google Inc.
A-Z
